Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

2015 PHEMCE Strategy and Implementation Plan Fact Sheet

Protecting health in a public health emergency requires an array of drugs, vaccines, and devices. Some of these may be commonly used day-to-day, while others may be unique to the threat – whether it is a chemical, biological, radiological, or nuclear threat, pandemic influenza, or an emerging infectious disease. Preparing these products for development, approval, and use means bringing together agencies with varied missions and requires careful planning. By working together, federal agencies are moving products forward at a remarkable pace to make them available for our nation and your community.

This collaboration happens through the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), a group made up of all the federal agencies involved in developing and providing the drugs, vaccines, and devices, collectively known as medical countermeasures (MCMs). The agencies work and plan together to be sure products progress as quickly and as economically as possible from early to final stages of development, are purchased if needed for the national stockpile, and can be effectively used in an emergency. The PHEMCE strives to eliminate gaps in preparedness and avoid redundancy. The 2015 PHEMCE Strategy and Implementation Plan (SIP) is a streamlined document that updates the 2014 PHEMCE SIP and includes all reporting requirements of the Public Health Service (PHS) Act, as amended by the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).

Collaborating for Results

The PHEMCE-wide response to the 2014-2015 Ebola epidemic in West Africa provides an excellent example of how the PHEMCE partners collaborated across missions areas during a real-time public health emergency. All components of the PHEMCE participated in and contributed to the response and this collaborative effort is summarized in the 2015 PHEMCE SIP.

The 2015 PHEMCE SIP also reports on other critical PHEMCE accomplishments achieved over the past year including:

  • Critical dose-sparing studies for anthrax vaccines were conducted
  • National planning guidance was released for mass patient decontamination following a chemical incident
  • Nine civilian MCM requirements documents were approved that specify MCM needs, ability to use, and product characteristics
  • Fourteen Emergency Use Authorizations were issued to facilitate the availability and use of MCMs needed during public health emergencies
  • Four MCMs achieved FDA licensure or approval

Setting Collective Priorities

In light of world events since the last strategy and implementation plan in 2014, the PHEMCE validated that their goals, objectives, and activities remained relevant in 2015, and then identified additional new priority activities to be pursued. PHEMCE priorities collectively cover medical countermeasure requirement-setting; basic research; advanced development; regulatory science management; procurement and stockpiling; response planning; distribution and dispensing; and monitoring, evaluation, and assessment.

Tracking and Monitoring Progress

To stay relevant in the face of ever-evolving threats to health, keep pace with technology, make the best use of available resources, and meet PHS Act (as amended by PAHPRA) requirements, the strategy and plan is updated and released annually.

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will continue to track, monitor, and evaluate the execution of all identified PHEMCE priorities and milestones.

Learn more and download the latest 2015 PHEMCE SIP.

  • This page last reviewed: December 22, 2015